These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24509352)

  • 1. [Pneumococcal disease prevention from early infancy to old age].
    Mészner Z
    Orv Hetil; 2014 Feb; 155(7):243-7. PubMed ID: 24509352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pneumococcal vaccination for children and adults].
    Albrich W
    Ther Umsch; 2016; 73(5):235-40. PubMed ID: 27268445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of pneumococcal vaccination in infants and young children].
    Adam D; Scholz H
    Klin Padiatr; 2001; 213(3):109-13. PubMed ID: 11417363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medical indications and effectiveness of the pneumococcal conjugate vaccine].
    Reinert RR
    Laryngorhinootologie; 2006 Apr; 85(4):291-8; quiz 299-300. PubMed ID: 16615030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New vaccines for the prevention of pneumococcal infections.
    Käyhty H; Eskola J
    Emerg Infect Dis; 1996; 2(4):289-98. PubMed ID: 8969245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
    Ludwig E; Mészner Z;
    Orv Hetil; 2014 Dec; 155(50):1996-2004. PubMed ID: 25481502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.
    Myint TT; Madhava H; Balmer P; Christopoulou D; Attal S; Menegas D; Sprenger R; Bonnet E
    Adv Ther; 2013 Feb; 30(2):127-51. PubMed ID: 23397399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults.
    Gaillat J
    Med Mal Infect; 2013 Jun; 43(6):215-21. PubMed ID: 23769155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
    Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
    Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.
    Azzari C; Martinón-Torres F; Schmitt HJ; Dagan R
    Pediatr Infect Dis J; 2014 Aug; 33(8):858-64. PubMed ID: 24618937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices
    MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine.
    Georgalis L; Mozalevskis A; Martínez de Aragón MV; Garrido-Estepa M
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):575-583. PubMed ID: 27844262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.